Treatment of acute myeloid leukemia with indolinone compounds
申请人:SUGEN, Inc.
公开号:US20030130280A1
公开(公告)日:2003-07-10
A method of treating acute myeloid leukemia in patient positive for FLT-3-ITD is described. The treatment is accomplished by administration of a compound of Formula I or II as defined herein.
4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
申请人:——
公开号:US20020187978A1
公开(公告)日:2002-12-12
The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
[EN] CYCLICSULFONATE PYRROLE INDOLINONES AS KINASE INHIBITORS<br/>[FR] CYCLICSULFONATE PYRROLE INDOLINONES EN TANT QU'INHIBITEURS DE KINASE
申请人:SUGEN INC
公开号:WO2005113561A1
公开(公告)日:2005-12-01
The invention provides compounds of structure of formula (I), and methods of their synthesis and use. Preferred compounds are useful as therapeutic agents, particularly for protein kinase related disorders such as cancer.
3-Methylidenyl-2-indolinone modulators of protein kinase
申请人:Sugen, Inc.
公开号:US06531502B1
公开(公告)日:2003-03-11
The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.